A DNA methylation assay for detection of ovarian cancer cells using a HpaII/MspI digestion-based PCR assay in an integrated microfluidic system

• Published in: Microfluidics and nanofluidics 2013-11, Vol.15 (5), p.575-585
• Main Authors: Wang, Chih-Hung, Lai, Hsien-Chih, Liou, Tong-Miin, Hsu, Keng-Fu, Chou, Cheng-Yang, Lee, Gwo-Bin
• Format: Article
• Language: English
• Subjects: Analytical Chemistry; Ascites; Biological and medical sciences; Biomedical Engineering and Bioengineering; Carcinogenesis; Deoxyribonucleic acid; DNA; Engineering; Engineering Fluid Dynamics; Female genital diseases; Gynecology. Andrology. Obstetrics; Medical sciences; Nanotechnology and Microengineering; Nucleic acids; Ovarian cancer; Research Paper; Tumors
• ISSN: 1613-4982; 1613-4990
• DOI: 10.1007/s10404-013-1179-8

Early and accurate diagnosis of cancer plays a very important role in favorable clinical outcomes. DNA methylation of tumor suppressor genes has been recognized as a diagnostic biomarker for early carcinogenesis. The presence of 5-methylcytosine in the CpG islands in the promoter region of a tumor suppressor gene is an important indicator of DNA methylation. However, the standard detection assay utilizing a bisulfite treatment and Hpa II/ Msp I endonuclease digestion is a tedious and lengthy process and requires a relatively large amount of DNA for testing. In this study, the methylated DNAs of various tumor suppressor genes, HAAO, HOXA9 and SFRP5, were chosen as candidates for detection of ovarian cancer cells. The entire experimental process for the DNA methylation assay, including target DNA isolation, Hpa II/ Msp I endonuclease digestion, and nucleic acid amplification has been realized in an integrated microfluidic system. The limit of detection using this developed system has been experimentally determined to be 10 2 cells/reaction. The entire process from sample loading to analysis of the results only took 3 h which is much faster than the existing protocols. Different sources of biosamples, such as cells, ascites and serums, could be detected with the methylated DNA, indicating that this developed microfluidic system could be adapted for clinical use. Thus, this developed microsystem may be a promising platform for the rapid and early diagnosis of cancers.